Taken together, these findings support the notion that in CRC cells, TGFβ1 treatment triggers metabolic reprogramming, and cells switch to undergo FAO, but not glycolysis or glutaminolysis, to meet the energy need during the process of EMT and invasion. Here, TGFB1 is linked to colorectal carcinoma.